Home Cart Sign in  
Chemical Structure| 139180-30-6 Chemical Structure| 139180-30-6

Structure of ZM241385
CAS No.: 139180-30-6

Chemical Structure| 139180-30-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ZM241385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.

Synonyms: ZM241385

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ZM241385

CAS No. :139180-30-6
Formula : C16H15N7O2
M.W : 337.34
SMILES Code : OC1=CC=C(CCNC2=NC3=NC(C4=CC=CO4)=NN3C(N)=N2)C=C1
Synonyms :
ZM241385
MDL No. :MFCD00908394
InChI Key :PWTBZOIUWZOPFT-UHFFFAOYSA-N
Pubchem ID :176407

Safety of ZM241385

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P280-P305+P351+P338

Related Pathways of ZM241385

GPCR

Isoform Comparison

Biological Activity

Target
  • Adenosine Receptor

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.96mL

0.59mL

0.30mL

14.82mL

2.96mL

1.48mL

29.64mL

5.93mL

2.96mL

References

[1]Wang Z, Che PL, Du J, Ha B, Yarema KJ. Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385. PLoS One. 2010 Nov 8;5(11):e13883.

[2]Lasley RD, Kristo G, Keith BJ, Mentzer RM Jr. The A2a/A2b receptor antagonist ZM-241385 blocks the cardioprotective effect of adenosine agonist pretreatment in in vivo rat myocardium. Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H426-31.

[3]Keddie JR, Poucher SM, et al. In vivo characterisation of ZM 241385, a selective adenosine A2A receptor antagonist. Eur J Pharmacol. 1996 Apr 22;301(1-3):107-13.

[4]Fernández P, Trzaska S, et al. Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine. Am J Pathol. 2008 Jun;172(6):1675-82.

[5]Byeon JJ, Park MH, et al. In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385. Molecules. 2020 Mar 2;25(5). pii: E1106.

[6]Varani K. Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. Br J Pharmacol. 1996 Apr;117(8):1693-701. doi: 10.1111/j.1476-5381.1996.tb15341.x.

[7] Poucher SM. The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Br J Pharmacol. 1995 Jul;115(6):1096-102.

[8]Pedata F. Adenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemia. Mediators Inflamm. 2014;2014:805198. doi: 10.1155/2014/805198.

 

Historical Records

Categories